Annovis Bio Inc expected to post a loss of 40 cents a share - Earnings Preview

Annovis Bio

11/08/2025 13:52

Annovis Bio Inc ANVS.N, ANVS.K is expected to  show no change in quarterly revenue when it reports  results on August 12 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for Annovis Bio Inc is for a loss of 40 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Annovis Bio Inc is $14.50, about 82.4% above its last closing price of $2.55

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.44
-0.36
-0.32
Beat
10.2
Dec. 31 2025
-0.29
-0.33
-0.43
Missed
-30.1
Sep. 30 2024
-0.54
-0.53
-0.97
Missed
-84.4​
Jun. 30 2024
-0.69
-0.63
-0.32
Beat
49.2
​​Mar. 31 2024
-0.84
-0.80
-0.10
Beat
87.5
Dec. 31 2023
-1.39
-1.30
-2.24
Missed
-71.7​
Sep. 30 2023
-1.06
-1.09
-1.63
Missed
-49.5
Jun. 30 2023
-1.11
-1.14
-1.07
Beat
6.3

This summary was machine generated August 11 at 12:52 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)